poba Adaptimmune ( NASDAQ: ADAP ) and Galapagos ( NASDAQ: GLPG ) have entered into an agreement to conduct a clinical proof-of-concept study for Adaptimmune’s TCR T-cell therapy candidate uza-cel for head and neck cancer. The companies plan to test the safety and efficacy of uza-cel using Galapagos’s decentralized manufacturing platform to produce the therapy. Galapagos will also have an option to exclusively license the product for global commercialization for the treatment of health and neck cancer and potentially solid tumor cancer indications.
Under the deal, Adaptimmune will receive $70M upfront and $30M in R&D funding. It will also be eligible to receive up to $100M in option exercise fees, up to $465M in various milestone payments and tiered royalties on any net sales. Adaptimmune will retain the development and commercial rights to uza-cel for the treatment of platinum-resistant ovarian cancer, according to a statement .
More on Adaptimmune Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript Adaptimmune: Huge Opportunity Amid Their Setback With Genentech Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune GAAP EPS of -$0.03 beats by $0.04, revenue of $5.
7M misses by $11.37M Adaptimmune Therapeutics gets $125M in financing from Hercules Capital.
